A 12-month randomized double blind clinical trial in 60 patients with active erosive hand osteoarthritis compared TNF blockade using adalimumab (40 mg fortnightly subcutaneous administration) with placebo. Whereas no benefit could be attributed to adalimumab overall, the drug significantly slowed erosive evolution in a subpopulation of patients with palpable soft tissue swelling at baseline (P = 0.009).
ORIGINAL RESEARCH PAPER
Verbruggen, G. et al. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. doi:10.1136/ard.2011.149849
Rights and permissions
About this article
Cite this article
TNF blockade slows joint damage progression. Nat Rev Rheumatol 8, 62 (2012). https://doi.org/10.1038/nrrheum.2011.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.215